ArticleJHEP reports : innovation in hepatology2024

Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies.

Claudia Campani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.